Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.75 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.75 |
| ▸ | FYN | P06241 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7402515 | 0.86 | FYN (0.69) | ALDH1A1CYP2D6CYP2C9ALOX15MAPK1 | |
| Pnu-99194A SCHEMBL2640137 | 0.86 | ALDH1A1 (1.00) | ALDH1A1CYP2D6CYP2C9ALOX15MAPK1 | |
| Pnu-99194A SCHEMBL29462288 | 0.86 | ALDH1A1 (1.00) | ALDH1A1CYP2D6CYP2C9ALOX15MAPK1 | |
| Pnu-99194A SCHEMBL8443806 | 0.85 | ALDH1A1 (0.97) | ALDH1A1CYP2D6CYP2C9ALOX15MAPK1 | |
| Pnu-99194A SCHEMBL29390413 | 0.85 | ALDH1A1 (0.97) | ALDH1A1CYP2D6CYP2C9ALOX15MAPK1 | |
| Pnu-99194A SCHEMBL29725518 | 0.78 | ALDH1A1 (1.00) | ALDH1A1CYP2D6CYP2C9ALOX15MAPK1 | |
| SCHEMBL8693500 | 0.78 | ALDH1A1 (0.72) | ALDH1A1CYP2D6CYP2C9ALOX15MAPK1 | |
| SCHEMBL8692999 | 0.78 | ALDH1A1 (0.71) | ALDH1A1CYP2D6CYP2C9ALOX15MAPK1 | |
| SCHEMBL8689915 | 0.77 | ALDH1A1 (0.81) | ALDH1A1CYP2D6CYP2C9ALOX15MAPK1 | |
| SCHEMBL8443852 | 0.77 | ALDH1A1 (0.66) | ALDH1A1CYP2D6CYP2C9ALOX15MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024062395-A1 | USE OF 5-METHOXY-2-AMINOINDAN (\"MEAI\") IN METHODS FOR TREATING METABOLIC SYNDROME | Clearmind Medicine Inc. (IL) | 2024-03-28 | — | — | WO | disclosed |
| CN-112500301-B | Regulator for longitudinal behavior | 以西结·戈兰 | 2024-02-13 | — | — | CN | disclosed |
| US-20230092839-A1 | ALCOHOLIC BEVERAGE SUBSTITUTES | Clearmind Medicine Inc. (CA) | 2023-03-23 | — | — | US | disclosed |
| US-11528924-B2 | Alcoholic beverage substitutes | Clearmind Medicine, Inc. (CA) | 2022-12-20 | — | — | US | disclosed |
| CN-114903134-A | Alcoholic beverage substitute | 以西结·戈兰 | 2022-08-16 | — | — | CN | disclosed |
| CN-114403335-A | Alcoholic beverage substitute | 以西结·戈兰 | 2022-04-29 | — | — | CN | disclosed |
| US-20210330608-A1 | BINGE BEHAVIOR REGULATORS | CLEARMIND LABS CORP. (CA) | 2021-10-28 | — | — | US | disclosed |
| US-20210330609-A1 | BINGE BEHAVIOR REGULATORS | CLEARMIND LABS CORP. (CA) | 2021-10-28 | — | — | US | disclosed |
| US-20210330607-A1 | BINGE BEHAVIOR REGULATORS | CLEARMIND LABS CORP. (CA) | 2021-10-28 | — | — | US | disclosed |
| US-11077072-B2 | Binge behavior regulators | Clearmind Medicine Inc. | 2021-08-03 | — | — | US | disclosed |
| US-10137096-B2 | Binge behavior regulators | CLEARMIND LABS CORP. (CA) | 2018-11-27 | — | — | US | disclosed |
| US-20180085326-A1 | BINGE BEHAVIOR REGULATORS | CLEARMIND LABS CORP. (CA) | 2018-03-29 | — | — | US | disclosed |
| US-20170360067-A1 | ALCOHOLIC BEVERAGE SUBSTITUTES | CLEARMIND LABS CORP. (CA) | 2017-12-21 | — | — | US | disclosed |
| EP-3230256-A1 | ALCOHOLIC BEVERAGE SUBSTITUTES | Golan, Ezekiel (CA) | 2017-10-18 | — | — | EP | disclosed |
| EP-3230255-A1 | BINGE BEHAVIOR REGULATORS | Golan, Ezekiel (CA) | 2017-10-18 | — | — | EP | disclosed |
| WO-2016092546-A1 | BINGE BEHAVIOR REGULATORS | GOLAN EZEKIEL (IL) | 2016-06-16 | — | — | WO | disclosed |
| WO-2016092547-A1 | ALCOHOLIC BEVERAGE SUBSTITUTES | GOLAN EZEKIEL (IL) | 2016-06-16 | — | — | WO | disclosed |
| US-5708018-A | 2-aminoindans as selective dopamine D3 ligands | PHARMACIA & UPJOHN COMPANY (US) | 1998-01-13 | — | — | US | disclosed |
| EP-0712387-A1 | 2-AMINOINDANS AS SELECTIVE DOPAMINE D3 LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 1996-05-22 | — | — | EP | disclosed |
| WO-1995004713-A1 | 2-AMINOINDANS AS SELECTIVE DOPAMINE D3 LIGANDS | THE UPJOHN COMPANY (US) | 1995-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180085326-A1 | BINGE BEHAVIOR REGULATORS | GABRB3, GABRB2, GABRB1 | ALDH1A1 847/4885CYP2D6 2059/4885CYP2C9 3171/4885 |
| US-20230092839-A1 | ALCOHOLIC BEVERAGE SUBSTITUTES | ADH1A, ADH5, ADH1C | ALDH1A1 34/4885CYP2D6 1235/4885CYP2C9 2012/4885 |
| US-10137096-B2 | Binge behavior regulators | GABRB3, GABRB2, GABRB1 | ALDH1A1 847/4885CYP2D6 2059/4885CYP2C9 3171/4885 |
| US-11077072-B2 | Binge behavior regulators | GABRB3, GABRB2, GABRB1 | ALDH1A1 847/4885CYP2D6 2059/4885CYP2C9 3171/4885 |
| US-20210330609-A1 | BINGE BEHAVIOR REGULATORS | GABRB3, GABRB2, GABRB1 | ALDH1A1 847/4885CYP2D6 2059/4885CYP2C9 3171/4885 |
| US-11528924-B2 | Alcoholic beverage substitutes | ADH1A, ADH5, ADH1C | ALDH1A1 34/4885CYP2D6 1235/4885CYP2C9 2012/4885 |
| US-20210330607-A1 | BINGE BEHAVIOR REGULATORS | GABRB3, GABRB2, GABRB1 | ALDH1A1 847/4885CYP2D6 2059/4885CYP2C9 3171/4885 |
| US-20210330608-A1 | BINGE BEHAVIOR REGULATORS | GABRB3, GABRB2, GABRB1 | ALDH1A1 847/4885CYP2D6 2059/4885CYP2C9 3171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.